arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Lunai Bioworks Inc.

LNAI
$2.41 ▼ -0.03 (-1.23%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
15 Visible periods
25 Metrics
Absolute Benchmarks
Price Chart
18
Health
Poor
Neutral Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, Lunai Bioworks Inc. shows mixed fundamentals. Return on Invested Capital remain bright spots. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $397.8M
Dividend Yield
Revenue Growth
Op. Margin
ROIC 699.2%
FCF / Share $-0.05
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

15-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$42.77K
↑ +30.5%
Net Income Profit after all expenses
$-178.01M
↓ -101.3%
FCF / Share Free cash flow per share
$-0.05
↑ +57.9%
Long-Term Debt Long-term obligations
$102.88K
↓ -85.9%

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • Return on Invested CapitalReturn on Invested Capital of 699.2% is excellent on an absolute basis (target > 10%)
warning

Bearish Risks

  • Interest CoverageInterest Coverage of -7695.62x is weak on an absolute basis (target > 5x)
  • FCF / Net IncomeFCF / Net Income of 0.04x is weak on an absolute basis (target > 1x)

Health Breakdown

Financial Health
18
Cash Quality
18

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 63 quarters